Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Holdings Increased by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Krystal Biotech, Inc. (NASDAQ:KRYSFree Report) by 10.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,007 shares of the company’s stock after purchasing an additional 283 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Krystal Biotech were worth $349,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in KRYS. Handelsbanken Fonder AB raised its stake in shares of Krystal Biotech by 1.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 107,200 shares of the company’s stock valued at $12,585,000 after buying an additional 2,000 shares in the last quarter. Legato Capital Management LLC increased its position in shares of Krystal Biotech by 16.4% during the 2nd quarter. Legato Capital Management LLC now owns 12,735 shares of the company’s stock worth $1,495,000 after purchasing an additional 1,795 shares in the last quarter. Jennison Associates LLC increased its position in shares of Krystal Biotech by 485.0% during the 3rd quarter. Jennison Associates LLC now owns 340,849 shares of the company’s stock worth $39,538,000 after purchasing an additional 282,583 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Krystal Biotech by 6.3% during the 3rd quarter. Victory Capital Management Inc. now owns 209,487 shares of the company’s stock worth $24,300,000 after purchasing an additional 12,448 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Krystal Biotech by 111.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock worth $83,000 after purchasing an additional 379 shares in the last quarter. 82.30% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KRYS. The Goldman Sachs Group began coverage on shares of Krystal Biotech in a research report on Monday, November 20th. They set a “buy” rating and a $160.00 target price for the company. Citigroup began coverage on shares of Krystal Biotech in a report on Thursday, October 12th. They set a “buy” rating and a $160.00 price objective on the stock. Finally, Cantor Fitzgerald increased their price objective on shares of Krystal Biotech from $160.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, December 13th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus target price of $148.78.

Read Our Latest Stock Analysis on Krystal Biotech

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 2,500 shares of the company’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total transaction of $325,000.00. Following the sale, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at $1,632,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $105.67, for a total value of $2,641,750.00. Following the completion of the transaction, the insider now owns 1,574,206 shares of the company’s stock, valued at $166,346,348.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 2,500 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $130.00, for a total transaction of $325,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at approximately $1,632,280. The disclosure for this sale can be found here. 17.00% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $111.19 on Thursday. Krystal Biotech, Inc. has a 52 week low of $70.51 and a 52 week high of $133.60. The company has a market capitalization of $3.14 billion, a P/E ratio of -75.64 and a beta of 0.76. The company’s 50 day moving average price is $118.65 and its two-hundred day moving average price is $116.89.

Krystal Biotech (NASDAQ:KRYSGet Free Report) last announced its quarterly earnings data on Monday, November 6th. The company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $3.89. The business had revenue of $8.60 million during the quarter, compared to the consensus estimate of $6.29 million. The business’s revenue for the quarter was up 8500.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.17) EPS. Analysts forecast that Krystal Biotech, Inc. will post -3.89 earnings per share for the current year.

Krystal Biotech Profile

(Free Report)

Krystal Biotech, Inc, a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.

See Also

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYSFree Report).

Institutional Ownership by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.